These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 4991617)

  • 21. [Study of tuberculostatic activity and blood concentration of new agents--rifampicin and ethambutol--in patients with pulmonary tuberculosis].
    Mkrtchian SV; Ushkin VV
    Antibiotiki; 1971 May; 16(5):472-7. PubMed ID: 5002224
    [No Abstract]   [Full Text] [Related]  

  • 22. [Bacterial resistance tests against secondary antitubercular agents--reliability of the routine methods].
    Tsukamura M
    Iryo; 1966 Mar; 20(3):241-50. PubMed ID: 5964831
    [No Abstract]   [Full Text] [Related]  

  • 23. [Experimental study of secondary tuberculostatic preparations in view of the resistance of mycobacteria to the primary drugs].
    Uvarova OA; Zemskova ZS; Stukalova BIa; Afanas'eva IuP
    Farmakol Toksikol; 1967; 30(4):474-7. PubMed ID: 4877410
    [No Abstract]   [Full Text] [Related]  

  • 24. [Criteria of clinical resistance of cycloserine, ethionamide and ethambutol].
    Okamoto K; Watanabe S; Terunuma K
    Kekkaku; 1970 Feb; 45(2):65-72. PubMed ID: 4985702
    [No Abstract]   [Full Text] [Related]  

  • 25. [Comparison of combination therapy of Capreomycin, ethionamide and cycloserin with that of kanamycin, ethionamide and cycloserin for the retreatment of pulmonary tuberculosis].
    Kitamoto O; Oka S; Kawamori Y; Gomi J; Sugiyama K
    Saishin Igaku; 1970 Jul; 25(7):1546-55. PubMed ID: 5451178
    [No Abstract]   [Full Text] [Related]  

  • 26. [Comparison among single, double and triple drug regimens in retreatment. (the seventh series of the trial, B)].
    Kekkaku; 1968 Jun; 43(6):199-207. PubMed ID: 5701828
    [No Abstract]   [Full Text] [Related]  

  • 27. [Cross resistance of Mycobacterium tuberculosis to streptomycin, kanamycin and viomycin].
    Makarevich NM; Mkrtchian SV; Afanas'eva IuP
    Antibiotiki; 1970 Apr; 15(4):345-51. PubMed ID: 4321321
    [No Abstract]   [Full Text] [Related]  

  • 28. [Clinical significance of resistance of Mycobacterium tuberculosis to chemoantibiotics].
    Lucchesi M; Zubiani M; Mancini P; Termine A
    Ann Ist Carlo Forlanini; 1967; 27(3):228-52. PubMed ID: 4972422
    [No Abstract]   [Full Text] [Related]  

  • 29. [Biological properties of Mycobacterium tuberculosis in relation to sensitivity to antibacterial preparations].
    Gol'shevskaia VI; Grishina TA; Karpenko OL; Safonova SG; Grishina TD
    Probl Tuberk; 1995; (4):37-40. PubMed ID: 7567869
    [TBL] [Abstract][Full Text] [Related]  

  • 30. FURTHER OBSERVATIONS ON THE KANAMYCIN RESISTANCE IN TUBERCULOUS PATIENTS.
    TSUKAMURA M; KASAI E; TSUKAMURA S
    Jpn J Tuberc; 1964 Jul; 12():27-33. PubMed ID: 14178489
    [No Abstract]   [Full Text] [Related]  

  • 31. Clinical experience with Myambutol in the treatment of polyresistant chronic tuberculosis.
    Urbancik B
    Antibiot Chemother; 1970; 16():281-6. PubMed ID: 5535614
    [No Abstract]   [Full Text] [Related]  

  • 32. [Heterogeneity of drug-resistant strains of Mycobacterium tuberculosis].
    Belogurova VP
    Probl Tuberk; 1970; 48(9):76-9. PubMed ID: 4996497
    [No Abstract]   [Full Text] [Related]  

  • 33. Studies on atypical mycobacteria. X. Experimental approach to the etiology of atypical mycobacteriosis.
    Ogawa T; Motomura K
    Kekkaku; 1971 Sep; 46(9):365-70. PubMed ID: 5122006
    [No Abstract]   [Full Text] [Related]  

  • 34. [On the variability of results of sensitivity determination in tuberculosis bacteria].
    Schmiedel A
    Z Tuberk Erkr Thoraxorg; 1968; 128(1):238-47. PubMed ID: 4973009
    [No Abstract]   [Full Text] [Related]  

  • 35. Rifampicin in daily and intermittent treatment of experimental murine tuberculosis, with emphasis on late results.
    Grumbach F; Canetti G; Le Lirzin M
    Tubercle; 1969 Sep; 50(3):280-93. PubMed ID: 4981497
    [No Abstract]   [Full Text] [Related]  

  • 36. [Evaluation of alternative regimen of SM-INH-PAS and KM-TH-CS at three months interval in initial treatment of far advanced pulmonary tuberculosis. A report of the 12th series controlled trial of chemotherapy].
    Kekkaku; 1972 Jun; 47(6):151-8. PubMed ID: 5081204
    [No Abstract]   [Full Text] [Related]  

  • 37. [Resistance of the tuberculosis bacillus to ethionamide, cycloserine, and viomycin noting coexistant resistance to streptomycin, isonicotinic acid, and para-aminosalicylic acid].
    Rudnicka M; Suszko K
    Med Dosw; 1966; 33():291-302. PubMed ID: 4287506
    [No Abstract]   [Full Text] [Related]  

  • 38. In vitro and in vivo studies to assess the suitability of anti-tuberculous drugs for use in intermittent chemotherapy regimens.
    Dickinson JM
    Bull Int Union Tuberc; 1968 Dec; 41():309-15. PubMed ID: 4179554
    [No Abstract]   [Full Text] [Related]  

  • 39. [Studies on the susceptibility of secondary anti-tuberculosis drugs (with special reference to the resistance-stabilities of cycloserine and ethionamide-resistant bacilli)].
    Hayashi S
    Kumamoto Igakkai Zasshi; 1970 Feb; 44(2):135-43. PubMed ID: 4986047
    [No Abstract]   [Full Text] [Related]  

  • 40. [A trial of treatment for pulmonary tuberculosis patients showing multiple resistance to anti-tuberculosis drugs. 1. A fundamental experiment of MIC of demethyl-chlortetracycline (LM) to M. tuberculosis and other mycobacteria].
    Takenaka T; Tsukamura M
    Kekkaku; 1970 Mar; 45(3):93-6. PubMed ID: 4987506
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.